The proposed Drug Resistance Index (DRI) is not a good measure of antibiotic effectiveness in relation to drug resistance
30 August 2019
The conclude that the DRI in its present form is not a useful tool to communicate to a wide audience. First, because its complexity makes it difficult to interpret, and second because the DRI may promote the unnecessary use of broad-spectrum antibiotics, potentially reversing many good initiatives undertaken to overcome and counter the global problem of antimicrobial resistance.
Further reading: BMJ Global Health
Author(s): Christina M J E Vandenbroucke-Grauls, Gunnar Kahlmeter, Jan Kluytmans, Marjolein Kluytmans-van den Bergh, Dominique L Monnet, Gunnar Skov Simonsen, Robert L Skov, Ute Wolff Sönksen, Andreas Voss
Effective Surveillance
OUR UNDERWRITERS
Unrestricted financial support by:
 |
Antimicrobial Resistance Fighter Coalition |
 |
Evotec |
 |
JSS University |
 |
INTERNATIONAL FEDERATION PHARMACEUTICAL MANUFACTURERS & ASSOCIATIONS |
Technology Database
Display your AMR Technology, Product and Service
Suppliers and Users of Technologies, Products and Services benefit from CAPI.
CAPI (Continuous AMR Partnering Initiative) unites Suppliers and Users worldwide with the aim to add to the curbing of AMR.
